The effects of a Gly16Arg ADRB2 polymorphism on responses to salmeterol or montelukast in Japanese patients with mild persistent asthma

Pharmacogenetics and Genomics

Volumn 24, Issue 5, 2014, Pages 246-255

  Konno, Satoshi ^a   Hizawa, Nobuyuki ^b   Makita, Hironi ^a   Shimizu, Kaoruko ^a   Sakamoto, Tohru ^b   Kokubu, Fumio ^c   Saito, Takefumi ^d   Endo, Takeo ^e   Ninomiya, Hiroki ^f   Iijima, Hiroaki ^g   Kaneko, Norihiro ^h   Ito, Yoichi M ⁱ   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^d The Center of Chest Diseases and Severe Motor Intellectual Disabilities   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION MITO MEDICAL CENTER   (Japan)

^f Noda City   (Japan)

^g Tsukuba Medical   (Japan)

^h KAMEDA MEDICAL CENTER   (Japan)

ⁱ HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CORTICOSTEROID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; MONTELUKAST; SALMETEROL XINAFOATE; ACETIC ACID DERIVATIVE; ADRB2 PROTEIN, HUMAN; QUINOLINE DERIVATIVE; SALBUTAMOL; SALMETEROL;

ADD ON THERAPY; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BEDTIME DOSAGE; BETA ADRENERGIC STIMULATION; BRONCHODILATATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CONTROL; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MILD PERSISTENT ASTHMA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ASTHMA; GENETICS; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY;

ACETATES; ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ALBUTEROL; ASTHMA; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; QUINOLINES; RECEPTORS, ADRENERGIC, BETA-2;

EID: 84898546196     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000043     Document Type: Article

References (45)

1. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363:1715-1726.
2. Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 18:975-985.
3. Rabinovitch N, Graber NJ, Chinchilli VM, Sorkness CA, Zeiger RS, Strunk RC, et al. Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma. J Allergy Clin Immunol 2010; 126:545-551.
4. Knuffman JE, Sorkness CA, Lemanske RF, Mauger DT, Boemer SJ, Martinez FD, et al. Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. J Allergy Clin Immunol 2009; 123:411-416.
5. Tantisira KG, Drazen JM. Genetics and pharmacogenetics of the leukotriene pathway. J Allergy Clin Immunol 2009; 124:422-427.
6. Klotsman M, York TP, Pillai SG, Vargas-Irwin C, Sharma SS, van den Oord EJCG, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007; 17:189-196.
7. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106:1088-1095.
8. Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103:1075-1080.
9. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 2011; 128:315-322.
10. Rodrigo GJ, Castro-Rodri'guez JA. Safety of long-acting b agonists for the treatment of asthma: clearing the air. Thorax 2012; 67:342-349.
11. Sears MR, Radner F. Safety of formoterol in asthma clinical trials: an update. Eur Respir J 2014; 43:103-114.
12. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
13. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthmarelated deaths. Ann Intern Med 2006; 144:904-912.
14. Wijesinghe M, Weatherall M, Perrin K, Harwood M, Beasley R. Risk of mortality associated with formoterol: a systematic review and meta-analysis. Eur Respir J 2009; 34:803-811.
15. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotypestratified, randomized, placebo-controlled cross-over trial. Lancet 2004; 364:1505-1512.
16. Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, et al. b2-receptor polymorphism in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010; 181:676-687.
17. Basu K, Palmer CN, Tavendale R, Lipworth BJ, Mukhopadhyay S. Adrenergic b2-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol 2009; 124:1188-1194.
18. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to long acting b2-agonist therapy: a pharmacogenetic analysis of two randomized studies. Lancet 2007; 370:2118-2125.
19. Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH, et al. Salmeterol response is not affected by b2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006; 118:809-816.
20. Lipworth BJ, Basu K, Donald HP, Tavendale R, Macgregor DF, Ogston SA, et al. Tailored second-line therapy in asthmatic children with the Arg16 genotype. Clin Sci 2013; 124:521-528.
21. Wechsler ME, Lehman E, Lazarus SC, Lemanske RF Jr, Boushey HA, Deykin A, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173:519-526.
22. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, et al. Effect of b2-adrenergic receptor polymorphism on response to long acting b2 agonist in asthma (LARGE trial): a genotypestratified, randomized, placebo-controlled, crossover trial. Lancet 2009; 374:1754-1764.
23. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, et al. Complex promoter and coding region beta 2- adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000; 97:10483-10488.
24. Kaneko Y, Masuko H, Sakamoto T, Iijima H, Naito T, Yatagai Y, et al. Asthma phenotypes in Japanese adults - their associations with the CCL5 and ADRB2 genotypes. Allergol Int 2013; 62:113-121.
25. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100:3184-3188.
26. Belfer I, Buzas B, Evans C, Hipp H, Phillips G, Taubman J, et al. Haplotype structure of the beta adrenergic receptor genes in US Caucasians and African Americans. Eur J Hum Genet 2005; 13:341-351.
27. Munakata M, Harada Y, Ishida T, Saito J, Nagabukuro A, Matsushita H, et al. Molecular-based haplotype analysis of the b2-adrenergic receptor gene (ADRB2) in Japanese asthmatics and non-asthmatic subjects. Allergol Int 2006; 55:191-198.
28. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59-65.
29. Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006; 117: 549-556.
30. Hasegawa T, Koya T, Sakagami T, Kagamu H, Arakawa M, Gejyo F, et al. The Asthma Control Test, Japanese Version (ACT-J) as a predictor of Global Initiative for Asthma (GINA) guideline-defined asthma control: analysis of a questionnaire-based survey. Allergol Int 2013; 62:323-330.
31. Terwillinger JD, Ott J. Handbook of human genetic linkage. Baltimore, MD: Johns Hopkins University Press; 1994.
32. Joos S, Miksch A, Szecsenyi J, Wieseker B, Grouven U, Kaiser T, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systemic review. Thorax 2008; 63:453-462.
33. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP, Haahtela T, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomized, comparative trial. BMJ 2003; 32:891-896.
34. Ilowite J, Webb R, Friedman B, Kerwin E, Bird SR, Hustad CM, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004; 92:641-648.
35. Lipworth B, Tan S, Delvin M, Aiken T, Baker R, Hendrick D. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 1998; 104:431-438.
36. Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327:1198-1203.
37. Lee DKC, Currie GP, Hall IP, Lima JJ, Lipworth BJ. The arginine-16 b2- adrenoceptor polymorphism predispose to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 2003; 57:68-75.
38. Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127:355-360.
39. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315-323.
40. Nadif R, Siroux V, Oryszczyn MP, Ravault C, Pison C, Pin I, Kauffmann F. Heterogeneity of asthma according to blood inflammatory patterns. Thorax 2009; 64:374-380.
41. McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, et al. A large subgroup of mild-to moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012; 185:612-619.
42. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57:875-879.
43. Telenga ED, Tideman SW, Kerstjens HA, Hacken NH, Timens W Postma DS, et al. Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response. Allergy 2012; 67: 1060-1068.
44. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175:783-790.
45. Price D, Popov TA, Bjermer L, Lu S, Petrovic R, Vandormael K, et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol 2013; 131:763-771.